Vericel Corp VCEL

Latest FY: 2025 Healthcare Biotechnology
Market Price $44.19
Market Cap $2.27B
P/E Ratio 138.08
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑16.5% YoY
$276.26M
3-Yr CAGR: 19.1%
Net Income ↑59.4% YoY
$16.52M
Net Margin: 6.0%
Free Cash Flow ↑525.9% YoY
$24.75M
FCF Yield: 1.09%
EPS (Diluted) ↑60.0% YoY
$0.32
Basic: $0.33
Return on Equity Efficiency
4.7%
ROA: 6.7%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (VCEL)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $54.4M $26.1M $-19.6M $-1.18 $-19.9M $-21.3M
FY 2017 $63.9M +17.5% $33.6M $-17.3M +11.7% $-0.52 +55.9% $-13.2M $-14.7M +31.0%
FY 2018 $90.9M +42.1% $58.7M $-8.1M +52.9% $-0.20 +61.5% $-0.4M $-3.1M +79.0%
FY 2019 $117.8M +29.7% $80.3M $-9.7M -18.8% $-0.22 -10.0% $-7.2M $-9.8M -217.1%
FY 2020 $122.0M +3.5% $82.0M $2.9M +129.6% $0.06 +127.3% $17.6M $14.9M +252.5%
FY 2021 $153.1M +25.5% $102.9M $-7.5M -360.9% $-0.16 -366.7% $29.0M $21.1M +41.3%
FY 2022 $163.7M +6.9% $109.1M $-16.7M -123.7% $-0.35 -118.7% $17.7M $10.1M -52.2%
FY 2023 $197.5M +20.7% $135.6M $-3.2M +81.0% $-0.07 +80.0% $35.3M $15.3M +51.6%
FY 2024 $237.2M +20.1% $172.1M $10.4M +425.6% $0.20 +385.7% $58.2M $-5.8M -138.0%
FY 2025 $276.3M +16.5% $205.6M $16.5M +59.4% $0.32 +60.0% $51.9M $24.7M +525.9%
$

Valuation

Market Price $44.19
Market Cap $2.27B
Enterprise Value N/A
P/E Ratio 138.08
P/B Ratio 6.36
FCF Yield 1.09%
Dividend Yield N/A
Shares Outstanding 51,068,200
%

Profitability & Margins

Gross Margin 74.42%
Operating Margin 4.00%
Net Margin 5.98%
Return on Equity (ROE) 4.66%
Return on Assets (ROA) 6.68%
Asset Turnover 1.12x
Revenue 3-Yr CAGR 19.06%
🛡️

Financial Health & Liquidity

Current Ratio 12.86
Cash Ratio 5.20
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $100.09M
Total Debt N/A
Book Value / Share $6.94
💧

Cash Flow Efficiency

Operating Cash Flow $51.91M
Capital Expenditures (CapEx) $27.16M
Free Cash Flow $24.75M
OCF / Revenue 18.79%
FCF / Revenue 8.96%
FCF 3-Yr CAGR 34.86%
🏷️

Per Share Metrics

EPS (Diluted) $0.32
EPS (Basic) $0.33
Dividends / Share N/A
Book Value / Share $6.94
EPS YoY Growth 60.00%
🏛️

Balance Sheet (FY 2025)

Total Assets $247.44M
Total Liabilities $19.24M
Stockholders' Equity $354.64M
Current Assets $247.44M
Current Liabilities $19.24M